Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/28606
Title: Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones
Authors: Vander Meeren, Sam
Heyrman, Bert
Renmans, Wim
Bakkus, Marleen
MAES, Brigitte 
De Raeve, Hendrik
Schots, Rik
Jochmans, Kristin
Issue Date: 2018
Publisher: SPRINGER
Source: ANNALS OF HEMATOLOGY, 97(7), p. 1219-1227
Abstract: High-count monoclonal B cell lymphocytosis (MBL) with a chronic lymphocytic leukemia (CLL) phenotype is a well-known entity, featuring 1-4% annual risk of progression towards CLL requiring treatment. Lymphoma-like MBL (L-MBL), on the other hand, remains poorly defined and data regarding outcome are lacking. We retrospectively evaluated 33 L-MBL cases within our hospital population and compared them to 95 subjects with CLL-like MBL (C-MBL). Diagnoses of L-MBL were based on asymptomatic B cell clones with Matutes score < 3, B cells < 5.0 x 10(3)/mu l, and negative computerized tomography scans. We found that median B cell counts were considerably lower compared to C-MBL (0.6 vs 2.3 x 10(3)/mu l) and remained stable over time. Based on immunophenotyping and immunogenetic profiling, most L-MBL clones did not correspond to known lymphoma entities. A strikingly high occurrence of paraproteinemia (48%), hypogammaglobulinemia (45%), and biclonality (21%) was seen; these incidences being significantly higher than in C-MBL (17, 21, and 5%, respectively). Unrelated monoclonal gammopathy of undetermined significance was a frequent feature, as the light chain type of 5/12 paraproteins detected was different from the clonal surface immunoglobulin. After 46-month median follow-up, 2/24 patients (8%) had progressed towards indolent lymphoma requiring no treatment. In contrast, 41% of C-MBL cases evolved to CLL and 17% required treatment. We conclude that clinical L-MBL is characterized by pronounced immune dysregulation and very slow or absent progression, clearly separating it from its CLL-like counterpart.
Notes: [Vander Meeren, Sam; Renmans, Wim; Bakkus, Marleen; Jochmans, Kristin] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Div Hematol, Dept Biol Clin, Brussels, Belgium. [Heyrman, Bert] ZNA Middelheim, Div Hematol, Dept Internal Med, Antwerp, Belgium. [Maes, Brigitte] Jessa Ziekenhuis, Div Hematol, Dept Clin Biol, Hasselt, Belgium. [De Raeve, Hendrik] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Pathol, Brussels, Belgium. [Schots, Rik] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Div Hematol, Dept Internal Med, Brussels, Belgium.
Keywords: Monoclonal B cell lymphocytosis; Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; MGUS; Immunophenotyping
Document URI: http://hdl.handle.net/1942/28606
ISSN: 0939-5555
e-ISSN: 1432-0584
DOI: 10.1007/s00277-018-3282-0
ISI #: 000433502600007
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
VanderMeeren2018_Article_Lymphoma-likeMonoclonalBCellLy.pdf
  Restricted Access
Published version666.3 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

1
checked on Sep 7, 2020

WEB OF SCIENCETM
Citations

2
checked on May 21, 2022

Page view(s)

122
checked on May 22, 2022

Download(s)

112
checked on May 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.